Coexpression of an unusual form of the EWS–WT1 fusion transcript and interleukin 2/15 receptor βmRNA in a desmoplastic small round cell tumour
- Y Nakanishi1,
- T Oinuma1,
- M Sano1,
- F Fuchinoue1,
- K Komatsu2,
- T Seki2,
- Y Obana1,
- M Tabata1,
- K Kikuchi1,
- M Shimamura3,
- K Ohmori3,
- N Nemoto1
- 1Department of Pathology, Nihon University School of Medicine, Tokyo, Japan
- 2Pathology Laboratory, Nihon University Itabashi Hospital, Tokyo
- 3Department of Thoracic Surgery, Nihon University School of Medicine
- Correspondence to: Dr N Nemoto Pathology Laboratory, Nihon University Itabashi Hospital, 30-1 Oyaguchi-kamimachi Itabasi-ku, Tokyo 173-8610, Japan; nemo{at}med.nihon-u.ac.jp
- Accepted 9 November 2005
Abstract
Background: The β chain of the interleukin 2/15 receptor (IL-2/15Rβ) is induced by the expression of the EWS–WT1. A case of desmoplastic small round cell tumour (DSRCT) expressing only an unusual EWS-WT1 treated by us is reported here.
Aim: To characterise an unusual form of EWS–WT1.
Methods: Frozen tissue sections of the axillary tumour were examined using a laser-assisted microdissection technique and reverse transcriptase polymerase chain reaction.
Results: The novel fusion of exon 8 of EWS and the defective exon 10 of WT1 (−KTS) was detected. Although it was an unusual form, the coexpression of the present EWS–WT1, IL-2/15Rβ and Janus kinase (JAK1) mRNA was detected in the tumour cells. IL-2 and signal transducers and activators of transcription (STAT5) mRNA were detected in both tumour and stromal cells.
Conclusion: The induction of the IL-2/15 receptor signalling pathway may contribute to tumorigenesis in DSRCT through a paracrine or an autocrine system, even though the EWS–WT1 was an unusual form.
- DSRCT, desmoplastic small round cell tumour
- EWS, Ewing’s sarcoma gene
- IL-2/15Rβ, interleukin 2/15 receptor β chain
- JAK, Janus kinase
- RT-PCR, reverse transcriptase polymerase chain reaction
- STAT5, signal transducers and activators of transcription
- WT1, Wilms’s tumour gene
Footnotes
-
Competing interests: None declared.
